Running title: mTOR kinase inhibition has opposing effects on AKT.
INTRODUCTION
Dysregulation of PI3K signaling is a common event in human cancer and mutations in multiple components of the pathway have been identified (1) (2) (3) . Activation of PI3K signaling in tumors is responsible for key features of the transformed phenotype, suggesting that inhibition of the pathway could be a useful therapeutic strategy (1, 4) .
The mTOR protein kinase is an important component of the PI3K/AKT pathway that controls cell proliferation, size and metabolism by integrating the effects of growth factors and the availability of nutrients and of energy. mTOR exists in two complexes: mTORC1 and mTORC2. mTORC1 contains the mTOR, Raptor, mLST8/GβL and PRAS40 proteins and controls cell size and protein translation via its two major substrates p70S6K and 4E-BP1 (5, 6) . Activated S6 kinase causes feedback inhibition of IGF-1/Insulin signaling by phosphorylating insulin receptor substrate 1 (IRS-1) and causing its degradation (7) . The mTORC2 complex contains mTOR, Rictor, mSin1, Protor and mLST8/GβL and is also activated in response to growth factor stimulation (8) . mTORC2 has been shown to phosphorylate AKT and SGK1 in a conserved hydrophobic domain (9, 10) . Phosphorylation of AKT at the Serine 473 site (S473) by mTORC2 enhances the catalytic activity of AKT already phosphorylated on Threonine 308 (T308) (11) . Thus, mTOR complexes function both upstream and downstream of AKT (12) .
Inhibitors of PI3K, AKT and mTOR are currently being developed as potential therapeutics for tumors in which the pathway is dysregulated (13, 14) . Initial studies have focused on inhibition of mTORC1 with the natural product rapamycin. Rapamycin hour as well, suggesting that dephosphorylation of AKT in response to mTOR kinase inhibition results in the inhibition of AKT kinase activity. Phosphorylation of S6K, AKT S473, and 4E-BP1 at S65 and T70 remain inhibited for at least twenty-four hours after drug addition, showing that mTOR kinase inhibition persists over this period. However, phosphorylation of AKT at the T308 site and of the AKT substrates GSK3-β, FOXO1/3, and PRAS40 rebound four hours after drug addition and reach pre-treatment levels eight to sixteen hours later (Figures 2A and B, panel 1) . The phosphorylation of FOXO is markedly enhanced compared to pretreatment levels. These data imply that inhibition of AKT in response to mTOR kinase inhibition is transient, despite continued inhibition of S473 phosphorylation. 4E-BP1 phosphorylation on T37/T46 also rises slightly compared to its nadir reaching a new steady state between eight and twenty-four hours after drug addition. Another mTOR kinase inhibitor, PP242, also caused transient inhibition of AKT T308 and AKT substrates phosphorylation suggesting that this is a general property of these drugs (Supplemental Figure 2) (32) .
Reactivation of AKT signaling could be due to a fall in drug concentration in the cell or to establishment of a new steady state of the signaling network with higher levels of AKT activity. To distinguish between these possibilities, either AZD8055 or a selective allosteric inhibitor of AKT1 and 2 was added to BT-474 ( Figure 2A , panels 2 and 3) and MDA-MB-468 cells ( Figure 2B , panels 2 and 3) eight hours after exposure of the cells to AZD8055. Re-addition of AZD8055 had essentially no effect; phosphorylation of AKT T308, AKT substrates and 4E-BP1 T37/46 remained elevated. In contrast, phosphorylation of AKT T308, GSK3-β, FOXO1/3, and PRAS40 were all-sensitive to the AKT inhibitor. This suggests that the increased phosphorylation of AKT substrates is due to reactivation of AKT. The residual phosphorylation of 4E-BP1 T37/46 was also sensitive to AKT, but not to mTOR kinase inhibition, suggesting that there may be AKTdependent, but mTOR-independent signals that regulate phosphorylation of this site.
These data and the persistent suppression of AKT S473 and S6K phosphorylation suggest that the reinduction of phosphorylation of AKT substrates is not due to decreased levels of drug in the cells. Furthermore, these data suggest that reinduction is due to reactivation of AKT and not another kinase.
To confirm that the rapid inhibition and subsequent reinduction of phosphorylation of AKT substrates is due to changes in AKT activity, we performed in vitro AKT kinase assays on immunoprecipates from cells treated with AZD8055 for up to twenty-four hours. AKT kinase activity declines within one hour of drug addition, reaches a nadir of fifteen percent of baseline at eight hours, and then rises to sixty percent of baseline by twenty-four hours after drug addition ( Figure 2C ).
The biphasic inhibition and subsequent mTOR-independent reactivation of AKT is likely due to parallel changes in T308 phosphorylation. In order to determine whether the initial rapid decline in T308 phosphorylation was due to the inhibition of mTORC2-dependent S473 phosphorylation, we utilized the AKT S473D mutant, which mimics constitutive phosphorylation of the site. BT-474 cells transfected with either AKT wildtype (WT) or AKT S473D were treated with AZD8055 for one or four hours.
Phosphorylation of endogenous AKT S473 (lower band) falls within one hour of drug treatment in both transfectants ( Figure 2D ). As expected, the binding of the antiphospho 473 antibody to the S473D mutant (upper band) is unaffected by the drug treatment, confirming that the aspartate substitution is phosphomimetic. Drug treatment does not decline; in fact, it increases after drug treatment. These data support the work of others that suggests that inhibition of AKT S473 phosphorylation causes a decline in T308 phosphorylation (9, 27, 32) . The rapid induction of T308 phosphorylation in mutant S473D confirms the conclusion that this induction is not due to declining intracellular drug concentrations. The rapid loss of T308 phosphorylation in WT AKT and rise in AKT S473D mutant suggest that, in these cells, two separate processes account for the decline and subsequent reinduction of T308 phosphorylation and AKT activity after mTOR kinase inhibition.
mTOR kinase inhibition leads to activation of PI3K
Phosphorylation of T308 is due to PI3K-dependent localization of PDK1, the T308 kinase, to the membrane. We asked whether the initial loss of T308 phosphorylation is counteracted by PI3K activation ( Figure 3A) . The p85 regulatory subunit of class 1 PI3K was immunoprecipitated from lysates of cells treated for four hours with drug and in vitro PI3K assays were performed on the precipitates in the presence of the AKT PH domain fused to the amino-terminus of GFP (33) . PIP3 binding to the PHdomain causes the fusion protein to associate with the plasma membrane. In control cells, the PH-GFP fusion protein is largely cytoplasmic and translocates to the membrane after IGF-1 stimulation of PI3K signaling ( Figure 3B ). Treatment of cells with AZD8055 also causes a marked translocation of the reporter to the membrane within four hours of its addition that was prevented by pre-treatment with the PI3K inhibitor wortmannin. Thus, AZD8055 rapidly activates PI3K activity in cells and this causes induction of PIP3 levels sufficient to translocate PH-domain binding proteins to the membrane.
mTOR kinase inhibition activates RTKs
We have previously observed that mTORC1 inhibition leads to activation of upstream receptor tyrosine kinase signaling (16) . Moreover, we and others have recently shown that PI3K and AKT inhibition induce expression and activation of multiple RTKs (34) (35) (36) . We, therefore, hypothesized that induction of PI3K activation by AZD8055 is mediated in part by growth factor receptor activation. An array of forty-two anti-phosphotyrosine receptor antibodies was used to assess whether RTK phosphorylation levels were induced in breast cancer cell lines after their exposure to the drug ( Figure 4A increasing five-fold by twenty-four hours after drug addition (P-EGFR-two-fold increase, P-HER4-two-fold and P-IGF1R/IR-six-fold) ( Figure 4C ).
AKT reactivation is dependent on HER kinase activation of PI3K
Reinduction of AKT signaling after its initial inhibition in AZD8055-treated cells is In the steady state more than eight hours after mTOR kinase inhibition, breast tumor cells are characterized by high levels of RTK phosphorylation and PI3K activity, phosphorylation of AKT T308, but not S473, phosphorylation of AKT substrates, and profound mTORC1 inhibition. To model the consequences of mTOR kinase inhibition in cells in which the relief of RTK feedback does not occur, we treated BT-474 cells with AZD8055 and lapatinib at the same time. We observed that the phosphorylation of EGFR, HER2 and HER3 was inhibited, and reinduction of AKT T308 and AKT substrates phosphorylation did not occur ( Figure 5B ). In these cells, chronic mTOR kinase inhibition is characterized by potent inhibition of both mTORC1 and AKT signaling. The data support the hypothesis that the effects of mTOR kinase inhibition will vary as a function of the degree of reactivation of upstream signaling.
Combined inhibition of the mTOR and AKT kinases induces tumor cell death
Reinduction of AKT activity in tumors treated with mTOR kinase inhibitors may attenuate the biologic and therapeutic effects of these drugs. To test this hypothesis, BT-474 cells were treated with AZD8055, an AKT inhibitor, or the combination for fortyeight hours. As seen in Figure 6A , the individual treatments had almost no effect on cell death (subG1 fraction) at 48 hours; however, the combination of both treatments greatly increased the level of apoptotic cells and the levels of cleaved PARP and cleaved caspase-3 ( Figure 6B ). Furthermore, the combination of both treatments inhibited the reinduction of AKT substrates due to mTOR kinase inhibition. These data support the hypothesis that restoration of AKT signaling helps to maintain cell survival under conditions in which mTOR kinase signaling is inhibited. 
HER kinase inhibition enhances the antitumor activity of AZD8055 in vivo
We previously showed that reactivation of AKT signaling might be in part responsible for the modest antitumor activity of mTORC1 inhibitors in patients (16) . This may be the case for mTOR kinase inhibitors as well, even though they potently inhibit mTORC1 and mTORC2 (25, 26) . We found that the maximal tolerated dose (MTD) of AZD8055 in mice is 150mg/kg, twice per week (data not shown). To determine if the induction of 
phosphorylation remains elevated at twenty-four hours despite loss of HER2 phosphorylation. This suggests that PI3K activity remains elevated, perhaps via activation of other HER3 or other receptors. In sum, the data suggest that chronic inhibition of mTOR kinase in vivo leads to a new steady state with persistent inhibition of mTORC1, activated AKT phosphorylated on T308 but not S473, and enough PI3K activation to support T308 phosphorylation.
To test whether inhibition of reactivated HER kinases sensitized the tumors to mTOR kinase inhibition; we evaluated the effects of combining AZD8055 with lapatinib on the growth of BT-474 xenografts ( Figure 7C ). We used a low dose of lapatinib administered three times weekly that had no antitumor activity when administered alone in order to distinguish sensitization of the tumor to mTOR kinase inhibition from additive activity of the two drugs. Chronic AZD8055 treatment causes complete arrest of tumor growth with little or no evidence for regression. After eleven days of treatment; the tumors began to re-grow, but more slowly than the controls. In contrast, combined treatment with AZD8055 and lapatinib caused persistent inhibition of growth over three weeks of treatment and was associated with thirty-five percent regression of the tumor.
DISCUSSION
AKT and mTOR are key enzymes controlling major cellular processes including cellular growth and metabolism; they each have been shown to regulate the activity of the other (12) . We have now shown that the selective mTOR kinase inhibitor AZD8055 is an effective inhibitor of both mTORC1 and mTORC2 activity but has complex effects on AKT signaling. It potently inhibits both S6K and 4E-BP1 phosphorylation in cells, confirming that it is a better mTORC1 inhibitor than rapamycin; also, AZD8055 completely inhibits the phosphorylation of AKT S473, consistent with its efficient inhibition of mTORC2 as well. Loss of AKT S473 phosphorylation is accompanied by concomitant inhibition of AKT T308 phosphorylation and kinase activity and causes decreased phosphorylation of multiple AKT substrates. Some of these results were predicted from Rictor knockdown experiments, in which AKT T308 phosphorylation was shown to be inhibited along with that of S473 (9) and have been obtained with other mTOR kinase inhibitors as well (27, 32) . They suggest that inhibition of mTORC2 will lead to the dephosphorylation of AKT at the T308 site and would lead to a more profound inhibition of AKT function than would be expected from dephosphorylation of AKT S473 alone. Thus, mTOR kinase inhibition should prevent the feedback activation of AKT signaling that has attenuated the response of patients with rapamycin therapy.
However, in tumor cells exposed to the drug, even though mTORC2 inhibition is potent and persistent, inhibition of phosphorylation of AKT T308 and of AKT substrates is only transient, occurring very quickly and then, four to eight hours after target inhibition, rising to baseline or higher than baseline levels. We show that this new steady state is due to reactivation of AKT after initial inhibition and not to a decrease in drug concentration in the cells. Reinduction of phosphorylation of AKT T308 and of AKT substrates is sensitive to AKT inhibition, but not to re-addition of the mTOR kinase inhibitor. Our data demonstrate that this reinduction is due to hyperactivation of PI3K.
The induction of PI3K activation is due to the relief of feedback inhibition of RTK signaling. Although we have shown that AZD8055 activates RTK signaling more potently that rapamycin, the increase in PI3K activity observed with the two drugs is Inhibition of mTORC2 leads to rapid inhibition of AKT S473 phosphorylation with attendant destabilization of phosphorylation at the T308 site. Release of feedback inhibition of receptor tyrosine kinase signaling function leads to activation of PI3K with the release of PIP3 which increases both PDK1 and AKT partition to the membrane and thus increases the rate of AKT T308 phosphorylation (37) . The loss and then the reinduction of T308 phosphorylation and AKT activity are the result of these two opposing effects. This is supported by our data; in cells expressing the AKT S473D mutant, AZD8055 causes a rapid monophasic rise in T308 phosphorylation that is not preceded by a decline ( Figure 2D ). In contrast, in cells in which relief of RTK feedback is inhibited, AZD8055 causes stable inhibition of phosphorylation of T308 without rebound ( Figure 5B ).
In cells in which mTOR kinase inhibitors relieve feedback inhibition of receptor tyrosine kinase leading to activation of PI3K, the result is a new steady state in which mTORC1 is potently inhibited and AKT is phosphorylated on T308 but not on the S473
site. This AKT species is activated and able to phosphorylate key substrates in the cell (Supplemental Figure 5) . Whether the activity of AKT monophosphorylated on the T308 site differs from that of AKT phosphorylated on both residues in the range or intensity of substrate phosphorylation remains to be determined. Previously, selective deletion of mTORC2 activity in MEFs with Rictor and mLST8 knockouts has been used to show that phosphorylation of most AKT substrates is mTORC2 independent but that phosphorylation of FOXO proteins depends on intact mTORC2 activity (38) . Of note, we show here that phosphorylation of multiple AKT substrates including FOXO declines and then rises with phosphorylation of AKT T308 showing that in this system, AKT T308 phosphorylation is enough to activate phosphorylation of AKT substrates, including FOXO.
The basis for the different effects of pharmacologic and genetic ablation of mTORC2 inhibition on FOXO-phosphorylation is unknown, but could have to do with the different cell types utilized in the studies. Our data show that mTOR kinase inhibition does initially inhibit AKT activity, but this inhibition is limited by relief of feedback inhibition of receptor tyrosine kinases, leading to induction of PI3K activity. The induction of PI3K activation is likely to be dependent on which receptor tyrosine kinases are activated and whether their ligands are present. It is conceivable that in certain lineages, feedback reactivation of receptor tyrosine kinases is weak or occurs in contexts in which ligands are not available. In such cases, mTOR kinase inhibition will lead to inhibition of AKT activity as well as inhibition of mTORC1 activity. In tumors in which mTORC1 inhibition leads to relief of RTK feedback, in the steady state, mTORC1 will be inhibited, but AKT, after initial inhibition, will be reactivated.
Emerging evidence suggests that dysregulated activation of onco-proteins leads to extensive feedback throughout the signaling network. We and others have partially characterized the relief of negative feedback induced by modest mTORC1 inhibition (35) . We show here that mTOR kinase inhibition leads to a third and more complex pattern of effects on these feedback pathways, with initial inhibition of AKT activity which then recovers. This is caused by re-induction of the phosphorylation of multiple HER kinases, IGF1-R, insulin receptor and other receptors that is much more marked than the one seen with rapamycin. This effect is likely due to a more complete inhibition of mTORC1 and to the transient potent inhibition of AKT activity by mTOR kinase inhibitors. This leads to an initial induction of both receptor expression and activity by these drugs but only the latter by rapamycin. Wild-Type (WT) or HA-S473D AKT plasmids and were treated for the indicated times with 2µM of AZD8055. Lysates were subjected to immunoblot analysis for P-AKT S473, T308, total AKT, HA and actin. The arrows refer to the exogenous and endogenous AKT species in the S473D transfectant. 
